Table 1.
Therapeutic approaches to regulate YAP/TAZ activity.
| Compound(s) | Mechanism | References |
|---|---|---|
| Dasatinib | Inhibits YES1 | [21] |
| Verteporfin, flufenamic acid | Disrupt YAP-TEAD interaction | [133,134] |
| YAP-like and VGLL4-like peptides | Disrupt YAP-TEAD interaction | [135,136,137] |
| XAV939, Inhibitor of WNT response 1 (IWR-1), G007-LK | Inhibit tankyrases to stabilize AMOTs | [138,139,140] |
| 093G9 | Monoclonal antibody against CYR61 | [141] |
| FG-3019 | Monoclonal antibody against CTGF | [142] |
| Foretinib, sunitinib | Small molecule inhibitors of AXL | [143] |
| Navitoclax (ABT-263) | Small molecule inhibitor of BCL-XL | [144] |
| Digitoxin | May inhibit WBP2-YAP interaction | [145,146] |
| 9E1 | Small molecule inhibitor of MST1 | [147] |
| BrP-LPA | Inhibits synthesis of LPA | [148] |
| ABC294640 | Small molecule inhibitor of SPHK2 | [149] |
| Statins | Inhibit mevalonate pathway | [150,151] |
| Antagomir against miR-135b | Derepression of LATS2, MOB1B | [152] |
| Antagomir against miR-130b | Derepression of MST1, SAV1 | [153] |
| MiR-302 mimic | Repression of MST1, LATS2, MOB1B | [154] |